{"id":"W3184066167","doi":"10.1016/j.annonc.2021.07.008","title":"Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Nonmelanoma Skin Cancer Studies","field":"Medicine","cited_by":200,"is_retracted":false,"has_abstract":false,"ca_institutions":"Jewish General Hospital","funders":"Merck Sharp and Dohme; Eisai; Les Laboratories Pierre Fabre; Merck KGaA; Mount Sylvia Diatomite; Roche; Novartis; Takeda Pharmaceutical Company; AbbVie; Sanofi; Merck; Bayer; Bristol-Myers Squibb; AstraZeneca; Amgen; Pfizer","keywords":"Medicine; Pembrolizumab; Tolerability; Interquartile range; Internal medicine; Cohort; Clinical endpoint; Response Evaluation Criteria in Solid Tumors; Phases of clinical research; Surgery; Oncology; Adverse effect; Gastroenterology; Clinical trial; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005751112,0.0003535693,0.001826645,0.0001302015,0.0002183055,0.00002739427,0.0002842764,0.0001191272,0.00008550266],"category_scores_gemma":[0.0009824333,0.0003243983,0.0001157913,0.0001858088,0.000198678,0.0001585684,0.0004249621,0.0002430835,0.000003559997],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00009722337,"about_ca_system_score_gemma":0.0007185772,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001036757,"about_ca_topic_score_gemma":0.0003975177,"domain_scores_codex":[0.9969882,0.0004637628,0.0009535066,0.0007647154,0.000280841,0.0005489417],"domain_scores_gemma":[0.9967276,0.001236084,0.0004739586,0.0005531774,0.000732535,0.0002766219],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7128288,0.04369286,0.0002288637,0.0003211346,0.0003036912,0.001465776,0.002130037,0.000003354794,0.003507504,0.00001615627,0.001489901,0.2340119],"study_design_scores_gemma":[0.7117618,0.2716337,0.0002239801,0.00005103646,0.000676732,0.0002874504,0.001480871,0.0003069892,0.005075461,0.00006900276,0.008166987,0.0002659846],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9865842,0.003634176,0.0001592646,0.001114935,0.0009444224,0.006053715,0.000151226,0.00002292752,0.001335135],"genre_scores_gemma":[0.9921953,0.0004054539,0.005166729,0.0007931049,0.0002076041,0.0006691603,0.00007927179,0.00005503354,0.000428349],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2337459,"threshold_uncertainty_score":0.9999208,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1210758423075117,"score_gpt":0.4482186709710368,"score_spread":0.3271428286635251,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}